Market data covers 2019, 2020 (estimated) and 2025 (forecasted). The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia Pacific, Rest of World). The market for next generation cancer diagnostics is analyzed in depth. The industry subsectors analyzed include DNA sequencing instruments, long-read DNA sequencing, informatics, PCR, droplet digital PCR, CTC capture and detection and liquid biopsy. The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from Jan. Key forces driving the market are enumerated. The report discusses several significant, large-scale research initiatives that contribute to cancer diagnostic development. The report also discusses, in-depth, various liquid biopsy platforms and how these compare with tissue-based testing. This report reviews the main next generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture and arrays/microfluidics. The market sizes for next generation cancer diagnostics are given for 2019, 2020 (estimated) and 2025 (forecasted). The scope of this report includes next generation diagnostic technologies, applications, industry subsegments, major funding initiatives, patents and companies. DUBLIN-( BUSINESS WIRE)-The "Next Generation Cancer Diagnostics: Technologies and Global Markets" report has been added to 's offering.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |